<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HDCA7A90F6FAD469FB6AE1927AC650F08" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1003 IH: VA Medicinal Cannabis Research Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-02-14</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1003</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230214">February 14, 2023</action-date><action-desc><sponsor name-id="C001110">Mr. Correa</sponsor> (for himself and <cosponsor name-id="B001301">Mr. Bergman</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HVR00">Committee on Veterans' Affairs</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Veterans Affairs to carry out a study and clinical trials on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder, and for other purposes.</official-title></form><legis-body id="HEF776702ECF045D8A853DF65A226CD9D" style="OLC"><section id="H08A381C714534985801CD3233786A2A8" section-type="section-one" changed="not-changed"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>VA Medicinal Cannabis Research Act of 2023</short-title></quote>.</text></section><section changed="not-changed" id="H45116F01A26D4B2AB62D13280DB03AA9"><enum>2.</enum><header>Definitions</header><text display-inline="no-display-inline">In this Act:</text><paragraph changed="not-changed" id="HC36296C159E34C05A4E52553EA456E42"><enum>(1)</enum><header>Covered veteran</header><text display-inline="yes-display-inline">The term <term>covered veteran</term> means a veteran who is enrolled in the patient enrollment system of the Department of Veterans Affairs established and operated under section 1705(a) of title 38, United States Code.</text></paragraph><paragraph changed="not-changed" id="HB389BCD7927B4B269D937B83134F2F4E"><enum>(2)</enum><header>Secretary</header><text display-inline="yes-display-inline"> The term <term>Secretary</term> means the Secretary of Veterans Affairs.</text></paragraph></section><section id="HD8469A64E06F46B29F8D818B6630EA1E" changed="not-changed"><enum>3.</enum><header>Department of Veterans Affairs large-scale, mixed methods, retrospective qualitative study on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder</header><subsection id="HFCC5764106224FC1BE0DE67BD8FFD8C6" changed="not-changed"><enum>(a)</enum><header>Study required</header><paragraph id="H88D90E1CE224448C824E23C68C6CC1E6" changed="not-changed"><enum>(1)</enum><header>In general</header><text>The Secretary, through the Office of Research and Development of the Department of Veterans Affairs, shall carry out a large-scale, mixed methods, retrospective, and qualitative study on the effects of cannabis on the health outcomes of covered veterans diagnosed with chronic pain and covered veterans diagnosed with post-traumatic stress disorder.</text></paragraph><paragraph id="H75DCAAA10E1C40FF90FDA523CC4AA2EA" changed="not-changed"><enum>(2)</enum><header>Observational study</header><text>The study required by paragraph (1) shall be conducted as an observational study on the effects of cannabis use on the health of covered veterans.</text></paragraph><paragraph id="H7AF70180372B4273955C1D26FBDAD3B5" changed="not-changed"><enum>(3)</enum><header>Elements</header><subparagraph id="H8FD9283859924B43B6CDF534C8E8D839" changed="not-changed"><enum>(A)</enum><header>In general</header><text>The study required by paragraph (1) shall—</text><clause id="H58A0B25A37E242CDA4B0B1116665206D" changed="not-changed"><enum>(i)</enum><text>triangulate a range of data sources;</text></clause><clause id="H7ABD6B7838B94099B7C652579031657D"><enum>(ii)</enum><text>compare the positive and negative health outcomes of covered veterans who use cannabis, utilizing outcomes that can be measured in an electronic health record of the Department and through data sets of the Department relating to claims for benefits under the laws administered by the Secretary; </text></clause><clause id="HEA91A028F34C45AD98C28CF716171A67" changed="not-changed"><enum>(iii)</enum><text>elicit the positive and negative outcomes of cannabis use for covered veterans through semi-structured interviews;</text></clause><clause id="H858FD7E53DD2468FBC439C2AC35D9F16" changed="not-changed"><enum>(iv)</enum><text>estimate current and future health system needs to address positive and negative outcomes of cannabis use for covered veterans;</text></clause><clause id="H5420DA5C714A4C32A8F820A8F6613540" changed="not-changed"><enum>(v)</enum><text>include a qualitative, open-ended survey provided to covered veterans who have sought care from the Department for chronic pain or post-traumatic stress disorder during the five-year period preceding the survey; and</text></clause><clause id="H592549F1177744D3B0971752ADFB35EB"><enum>(vi)</enum><text>include an assessment of—</text><subclause id="H8BD171FB85BF48BEBCA46CE120178E6C"><enum>(I)</enum><text>all records within the Veterans Health Administration for covered veterans participating in the study; and</text></subclause><subclause id="H117442526E1640DFB04A9DC2D77ED6CE"><enum>(II)</enum><text>all records within the Veterans Benefits Administration for covered veterans participating in the study. </text></subclause></clause></subparagraph><subparagraph id="H9BBB0AF16C65418F88F1FAEAC51FBBB7" changed="not-changed"><enum>(B)</enum><header>Health outcomes</header><text>A comparison of health outcomes under subparagraph (A)(ii) shall include an assessment of the following:</text><clause id="H52F2198FFE374E3BB7DD20DB3B1E775F"><enum>(i)</enum><text>The reduction or increase in opiate use or dosage.</text></clause><clause id="HD244039DDD544E2AB69E33EEEF282D27"><enum>(ii)</enum><text>The reduction or increase in benzodiazepine use or dosage.</text></clause><clause id="HF1D3414AF98C41F7BC8A2EFAA27E3EA1" changed="not-changed"><enum>(iii)</enum><text>The reduction or change in use of other types of medication.</text></clause><clause id="HFD37E28023434E68B410DA293F36437E" changed="not-changed"><enum>(iv)</enum><text>The reduction or increase in alcohol use.</text></clause><clause changed="not-changed" id="H517BD29C38144BE7B3BBEE4ED31834DB"><enum>(v)</enum><text>The reduction or increase in the prevalence of substance abuse disorders.</text></clause><clause id="HD40AFCDC90B34EF8B629F166A6A2D8CD" changed="not-changed"><enum>(vi)</enum><text>Sleep quality.</text></clause><clause id="H21E1A3D7F7CA421FA73E66EB5C2BB445" changed="not-changed"><enum>(vii)</enum><text>Osteopathic pain (including pain intensity and pain-related outcomes).</text></clause><clause id="H0D1A2644641848BBAD2716F64B7EBC60" changed="not-changed"><enum>(viii)</enum><text>Agitation.</text></clause><clause id="H19895D37B33D47EF99EFEF1A7B18058D" changed="not-changed"><enum>(ix)</enum><text>Quality of life.</text></clause><clause id="HFADF9516239647B6BBEDC7C1D211B852" changed="not-changed"><enum>(x)</enum><text>Mortality and morbidity.</text></clause><clause id="HF65E854F4CFE42A0958692E1C9B2DE9B" changed="not-changed"><enum>(xi)</enum><text>Hospital readmissions.</text></clause><clause id="HB266610B01F547AC8BCB576C94503AA6" changed="not-changed"><enum>(xii)</enum><text>Any newly developed or exacerbated health conditions, including mental health conditions.</text></clause></subparagraph></paragraph></subsection><subsection changed="not-changed" id="H388FE53029704B80A7FC95743F3DC0D6"><enum>(b)</enum><header>Implementation</header><text>Not later than 180 days after the date of the enactment of this Act, the Secretary shall commence the implementation of the study required by subsection (a)(1). </text></subsection><subsection changed="not-changed" id="HF24BA5A4662E4AA09BD5F487B472489F"><enum>(c)</enum><header>Duration of study</header><text>The study required by subsection (a)(1) shall be carried out for an 18-month period.</text></subsection><subsection id="HF3A4128A4DDE4CF798E879295E5263CA" changed="not-changed"><enum>(d)</enum><header>Report</header><paragraph changed="not-changed" id="HC8E863F12ECE4532A6E27CD2E0C7CAAC"><enum>(1)</enum><header>In general</header><text>Not later than 90 days after the completion of the study required by subsection (a)(1), the Secretary shall submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report on the study.</text></paragraph><paragraph changed="not-changed" id="HFCFEE30AA809496F8E45F8FBDFCB0E63"><enum>(2)</enum><header>Ability to conduct clinical trials</header><text>The Secretary shall include in the report required by paragraph (1) an assessment of whether the Secretary is able to meet the criteria necessary to conduct the clinical trials required under section 4, including consideration of subsection (e)(1) of such section.</text></paragraph></subsection></section><section id="H1F2C887F7F2A4144AF8413598FD495A3" changed="not-changed"><enum>4.</enum><header>Department of Veterans Affairs clinical trials on the effects of cannabis on certain health outcomes of veterans with chronic pain and post-traumatic stress disorder</header><subsection id="HF259BA6A604448DF9C95E88BCA2A7473" changed="not-changed"><enum>(a)</enum><header>Clinical trials required</header><paragraph id="H53C652C85F9949888F25CC271F7C5FD0" changed="not-changed"><enum>(1)</enum><header>In general</header><text>If the Secretary indicates in the report required by section 3(d) that the Secretary is able to meet the criteria necessary to proceed to clinical trials, commencing not later than 180 days after the submittal of that report, the Secretary shall carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>), on the health outcomes of covered veterans diagnosed with chronic pain and covered veterans diagnosed with post-traumatic stress disorder.</text></paragraph><paragraph id="H76278F767BBB48078C6E61837BB8DECF" changed="not-changed"><enum>(2)</enum><header>Considerations</header><text>The clinical trials required by paragraph (1) shall include, as appropriate, an evaluation of key symptoms, clinical outcomes, and conditions associated with chronic pain and post-traumatic stress disorder, which may include—</text><subparagraph id="HA33019FE974B4B1189564E65CE1EAAB4" changed="not-changed"><enum>(A)</enum><text>with respect to covered veterans diagnosed with chronic pain, an evaluation of the effects of the use of cannabis on—</text><clause id="HEC9D305325604CEE83593B292B66265D" changed="not-changed"><enum>(i)</enum><text>osteopathic pain (including pain intensity and pain-related outcomes);</text></clause><clause id="H4AED9E18E55540B1A1DB1B81BA8FABE5" changed="not-changed"><enum>(ii)</enum><text>the reduction or increase in opioid use or dosage;</text></clause><clause id="H2768636E57804C3C8A313D50E0BAD74A" changed="not-changed"><enum>(iii)</enum><text>the reduction or increase in benzodiazepine use or dosage;</text></clause><clause id="H371ABAC359BD448EB66B44541DAEFE4B" changed="not-changed"><enum>(iv)</enum><text>the reduction or increase in alcohol use;</text></clause><clause id="H189B12CBE8184D7E9D41ACC63A321113" changed="not-changed"><enum>(v)</enum><text>the reduction or increase in the prevalence of substance use disorders;</text></clause><clause id="H70DEF5D6613B4FDBB1D1B3CE64A847A3" changed="not-changed"><enum>(vi)</enum><text>inflammation;</text></clause><clause id="H2A6536DACE3E4F75B771B74FD43DAE25" changed="not-changed"><enum>(vii)</enum><text>sleep quality;</text></clause><clause id="H09B0D30C4E574288AE927E9AF06A81EE" changed="not-changed"><enum>(viii)</enum><text>agitation;</text></clause><clause id="HB61A2E64CDAE40378B622F29CB88BA21" changed="not-changed"><enum>(ix)</enum><text>quality of life;</text></clause><clause changed="not-changed" id="HB11A41101FFB4F3BA7FA75445A0BED47"><enum>(x)</enum><text>exacerbated or new mental health conditions; and</text></clause><clause changed="not-changed" id="HB7FCC234755445CB95C50E360929F89F"><enum>(xi)</enum><text>suicidal ideation.</text></clause></subparagraph><subparagraph id="H61C1E2872B3F4C6E94735409A37921E5" changed="not-changed"><enum>(B)</enum><text>with respect to covered veterans diagnosed with post-traumatic stress disorder, an evaluation of the effects of the use of cannabis on—</text><clause id="H39A0903C865C4EF79D3BD49F9FFB04D1" changed="not-changed"><enum>(i)</enum><text>the symptoms of post-traumatic stress disorder (PTSD) as established by or derived from the clinician administered PTSD scale, the PTSD checklist, the PTSD symptom scale, the post-traumatic diagnostic scale, and other applicable methods of evaluating symptoms of post-traumatic stress disorder;</text></clause><clause id="HBF7A3929714347F7BB5F4659AFF2A24C" changed="not-changed"><enum>(ii)</enum><text>the reduction or increase in benzodiazepine use or dosage;</text></clause><clause id="H9DD23ED929CD4A2DBC63988DA70B551C" changed="not-changed"><enum>(iii)</enum><text>the reduction or increase in alcohol use;</text></clause><clause id="HB8A9F1292A9345BD9E735B5BDB49D53F" changed="not-changed"><enum>(iv)</enum><text>the reduction or increase in the prevalence of substance use disorders;</text></clause><clause id="HA65E751C213F4A629C8E3395ACD2CF3B" changed="not-changed"><enum>(v)</enum><text>mood;</text></clause><clause id="H391CE57D317F426F85E5F99A50A28DA1" changed="not-changed"><enum>(vi)</enum><text>anxiety;</text></clause><clause id="HCDA13D62610749D7955FC3C6BFF0AE2D" changed="not-changed"><enum>(vii)</enum><text>social functioning;</text></clause><clause id="H741FD58F33CE4AD193D6A6BAF06EFDB5" changed="not-changed"><enum>(viii)</enum><text>agitation;</text></clause><clause id="HCF420A8B577D4AE585D17F184B0B192D" changed="not-changed"><enum>(ix)</enum><text>suicidal ideation; and</text></clause><clause id="HB6D7967EECF447D791B41F34B67F7F50" changed="not-changed"><enum>(x)</enum><text>sleep quality, including frequency of nightmares and night terrors.</text></clause></subparagraph></paragraph><paragraph id="HCEE2F87007CF405185CC2F26EAD90CB0" changed="not-changed"><enum>(3)</enum><header>Optional elements</header><text>The clinical trials required by paragraph (1) may include, as appropriate, an evaluation of the effects of the use of cannabis to treat chronic pain and post-traumatic stress disorder on other symptoms, clinical outcomes, and conditions not covered by paragraph (2), which may include—</text><subparagraph id="H828A1E1812A8479BB209AB4362364349" changed="not-changed"><enum>(A)</enum><text>pulmonary function;</text></subparagraph><subparagraph id="H01F462FF1D2E4546952C55526FF723F0" changed="not-changed"><enum>(B)</enum><text>cardiovascular events;</text></subparagraph><subparagraph id="HEB1874BAA063402886FAE4370861F0A3" changed="not-changed"><enum>(C)</enum><text>head, neck, and oral cancer;</text></subparagraph><subparagraph id="H3F2A912BF11445589FBE90403B9E6452" changed="not-changed"><enum>(D)</enum><text>testicular cancer;</text></subparagraph><subparagraph id="HEA508A73219D4B93BDE00971AED90DB1" changed="not-changed"><enum>(E)</enum><text>ovarian cancer;</text></subparagraph><subparagraph id="H1666CF30C33E418CAE6BB10BA4949C7F" changed="not-changed"><enum>(F)</enum><text>transitional cell cancer;</text></subparagraph><subparagraph id="HFCEAE1594ABB4F74A9E679867D175800" changed="not-changed"><enum>(G)</enum><text>intestinal inflammation;</text></subparagraph><subparagraph id="HD0C850E88E2B4F5782E9F6A77C680C5B" changed="not-changed"><enum>(H)</enum><text>motor vehicle accidents; or</text></subparagraph><subparagraph id="H43F33D0077104A9BA71FECA59C60728F" changed="not-changed"><enum>(I)</enum><text>spasticity.</text></subparagraph></paragraph></subsection><subsection id="H2F19D178C9C941949FBB151DC7F7906E" changed="not-changed"><enum>(b)</enum><header>Long-Term observational study</header><text>The Secretary may carry out a long-term observational study of the participants in the clinical trials required by subsection (a).</text></subsection><subsection id="HF7C0DA2B409E4786994480C214008622" changed="not-changed"><enum>(c)</enum><header>Type of cannabis</header><paragraph id="H63EF67F46B08455F92323A16AB27F967" changed="not-changed"><enum>(1)</enum><header>In general</header><text>In carrying out the clinical trials required by subsection (a), the Secretary shall study varying forms of cannabis, including whole plant raw material and extracts, and may study varying routes of administration.</text></paragraph><paragraph id="H14FCB49AA6AB42889CF3BE88852733EA" changed="not-changed"><enum>(2)</enum><header>Plant cultivars</header><text>Of the varying forms of cannabis required under paragraph (1), the Secretary shall study plant cultivars with varying ratios of tetrahydrocannabinol to cannabidiol.</text></paragraph></subsection><subsection id="H1900A3997D1B47E4B85864BC53216D54" changed="not-changed"><enum>(d)</enum><header>Implementation</header><text>Not later than 18 months after the date of the enactment of this Act, the Secretary shall—</text><paragraph id="H067ABF71135C425DB77171DD9302A4F1" changed="not-changed"><enum>(1)</enum><text>develop a plan to implement this section and submit such plan to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives; and</text></paragraph><paragraph id="HA420B88647454F6586D6682DAE0C084A" changed="not-changed" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text>issue any requests for proposals the Secretary determines appropriate for such implementation. </text></paragraph></subsection><subsection display-inline="no-display-inline" changed="not-changed" commented="no" id="H2DCEDA7BDF224DCDA29A28337A45CD2C"><enum>(e)</enum><header>Termination of clinical trials</header><paragraph display-inline="no-display-inline" changed="not-changed" commented="no" id="HDA194C16CA5741A2AC71CAEF5C5EB06A"><enum>(1)</enum><header>Clinical guideline requirements or excessive risk</header><text>The Secretary may terminate the clinical trials required by subsection (a) if the Secretary determines that the Department of Veterans Affairs is unable to meet clinical guideline requirements necessary to conduct such trials or the clinical trials would create excessive risk to participants.</text></paragraph><paragraph display-inline="no-display-inline" changed="not-changed" commented="no" id="H0B1FD23C8B7C493AA7BE3CB13DAAFF0C"><enum>(2)</enum><header>Completion upon submittal of final report</header><text>The Secretary may terminate the clinical trials required by subsection (a) upon submittal of the final report required under subsection (f)(2).</text></paragraph></subsection><subsection id="HFFB4FD952CBF4E80AAB5E72445BEB413" changed="not-changed"><enum>(f)</enum><header>Reports</header><paragraph changed="not-changed" id="H335287AB92E34343B04584B6B4E99476"><enum>(1)</enum><header>Periodic reports</header><text>During the five-year period beginning on the date of the commencement of clinical trials required by subsection (a), the Secretary shall submit periodically, but not less frequently than annually, to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives reports on the implementation of this section.</text></paragraph><paragraph changed="not-changed" id="H625292466F194566A7D5091F1A6B451A"><enum>(2)</enum><header>Final report</header><text>Not later than one year after the completion of the five-year period specified in paragraph (1), the Secretary shall submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a final report on the implementation of this section.</text></paragraph></subsection></section><section id="H84D302715A7C4715B69FF882DE761E0F"><enum>5.</enum><header>Administration of study and clinical trials</header><subsection id="HF0E53EA52A1E445F89ED32C92BDDC12C" changed="not-changed"><enum>(a)</enum><header>Demographic representation</header><text>In carrying out the study required by section 3 and the clinical trials required by section 4, the Secretary shall ensure representation in such study and trials of demographics that represent the population of veterans in the United States, as determined by the most recently available data from the American Community Survey of the Bureau of the Census.</text></subsection><subsection id="H59A71F39EB5A48A5B58A4BC2B3BD2A84" changed="not-changed"><enum>(b)</enum><header>Data preservation</header><text>The Secretary shall ensure that the study required by section 3 and the clinical trials required by section 4 include a mechanism to ensure—</text><paragraph id="HDCE4508A479E42E3A63BE24D05070417" changed="not-changed"><enum>(1)</enum><text>the preservation of all data, including all data sets and survey results, collected or used for purposes of such study and trials in a manner that will facilitate further research; and</text></paragraph><paragraph id="H3F2FD9459B8E430CA96958ADA4B97DF8" changed="not-changed"><enum>(2)</enum><text>registration of such data in the database of privately and publicly funded clinical studies maintained by the National Library of Medicine (or successor database).</text></paragraph></subsection><subsection changed="not-changed" id="HA27F1984AA6944B1ABF3AEE99C11A90B"><enum>(c)</enum><header>Anonymous data</header><text>The Secretary shall ensure that data relating to any study or clinical trial conducted under this Act is anonymized and cannot be traced back to an individual patient.</text></subsection><subsection id="HD314016B2FDD4D498A255083CEC572EB" changed="not-changed"><enum>(d)</enum><header>Effect on other benefits</header><text>The eligibility or entitlement of a covered veteran to any other benefit under the laws administered by the Secretary or any other provision of law shall not be affected by the participation of the covered veteran in the study under section 3, a clinical trial under section 4(a), or a study under section 4(b).</text></subsection><subsection id="H83D66FC3390147C7A846FACE237C379C" changed="not-changed"><enum>(e)</enum><header>Effect on other laws</header><text>Nothing in this Act shall affect or modify—</text><paragraph id="H241C11BD216146498434C96AAC2FA99A" changed="not-changed"><enum>(1)</enum><text>the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>);</text></paragraph><paragraph id="H79692291557646BAA7F9D61AF543A0A4" changed="not-changed"><enum>(2)</enum><text>section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>); or</text></paragraph><paragraph id="HEDAA10BF675A4A57875DA1761116121A" changed="not-changed"><enum>(3)</enum><text>the authority of the Commissioner of Food and Drugs and the Secretary of Health and Human Services—</text><subparagraph id="H628B1DE572EA421292426038F276271E" changed="not-changed"><enum>(A)</enum><text>under—</text><clause id="H3CBA98E75BA94A0EBAD48CD27B6D4B1B" changed="not-changed"><enum>(i)</enum><text>the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>); or</text></clause><clause id="H0CDC4C0194EF408DB6B07141B20438E8" changed="not-changed"><enum>(ii)</enum><text>section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>); or </text></clause></subparagraph><subparagraph id="H0C7B9632DFE340AEAD69ADC0A67E3503" changed="not-changed" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text>to promulgate Federal regulations and guidelines pertaining to cannabidiol, marijuana, or other subject matter addressed in this Act. </text></subparagraph></paragraph></subsection></section></legis-body></bill> 

